Effect of Alfacalcidol on Anemia in Renal Failure Patients

Document Type : Original Article

Authors

1 Department of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University, Egypt.

2 Department of Pharmacology & Toxicology, Faculty of Medicine, Suez Canal University, Egypt.

3 Department of Internal Medicine, Faculty of Medicine, Suez Canal University, Egypt

Abstract

Background: Anemia is a major feature of chronic kidney disease (CKD). Additionally, secondary hyperparathyroidism (SHPT) has been associated with anemia in uremic patients. Administration of active vitamin D metabolites like alfacalcidol is established for PTH suppression and may also play a role in hematopoiesis. Aim:To investigate the effect of alfacalcidol on anemia and SHPT with end stage renal failure patients underwent hemodialysis. Subjects and Methods: In the present study 17 anemic patients over 15years, with serum level of PTH greater than 500pg/ml. The study was carried out by means of data collection and analysis of serum parathyroid hormone (PTH) and hemoglobin (Hb) levels in these patients. Results: Low serum PTH levels were detected in uremic patients treated with alfacalcidol. Also, in these patients, Hb levels increased. Serum PTH and Hb levels were inversely correlated. Conclusions: High-dose alfacalcidol can decrease serum PTH levels and elevate Hb level in uremic patients showing considerable resistance to Epoetin.
 
 

Keywords

Files

Share

How to cite

Statistics